Fewer than 1 in 3 children with hepatitis C (HCV) see a clinician for care, and fewer than 1 in 8 receive treatment. HCV cases in children are rising, yet access to treatment is limited, especially for Black children, according to a new retrospective cohort analysis published in Pediatrics. Treatment entails direct-acting antiviral agents, for which 95% of patients have no detectable trace of the virus 12 weeks after treatment. “HCV is a silent killer,” said Megan Rose Curtis, MD, MS, the...

Industry Buzz “IL-23s will be most useful in patients who have a large amount of psoriatic skin involvement. They are much better at clearing the skin vs TNF inhibitors.” — Stella Bard, MD, rheumatologist at Arthritis & Rheumatology Care PC Brooklyn “IL-23 inhibitors are a great option for patients who have concomitant inflammatory bowel disease, since IL-17 inhibitors are contraindicated in this disease population.” — Amy Kehl, MD, a board-certified rheumatologist at Providence Saint John’s...

Industry Buzz “[Biologics] overall have a high risk-to-benefit ratio, especially when the risk of certain opportunistic infections is mitigated by vaccinations.” — Julius Birnbaum, MD, MHS, Rheumatologist, Associate Professor of Rheumatology at the University of Pittsburgh Medical Center “IL-23s have a much lower risk of infection than TNF inhibitors. IL-23s can be a great alternative for people who cannot take a TNF inhibitor, who cannot tolerate it, or who have not responded to TNF...